Atossa Therapeutics, Inc. Common Stock ATOS
i
Market datapartial · fetched 2026-11-04T06:58:30.819Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-11-20
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-03T21:17:35.344568359Z
FundamentalsAlpha Vantage · unavailable
Atossa Therapeutics, Inc. Common Stock options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | ||||||
| 25Δ | ||||||
| 30Δ | 2.01 | 337.6% | 32.5% | |||
| 35Δ | 2.11 | 317.3% | 29.4% | |||
| 40Δ | 2.22 | 297.1% | 26.4% | |||
| 45Δ | 2.32 | 276.9% | 23.3% | |||
| 50Δ | 2.41 | 191.1% | 21.8% | 2.42 | 256.7% | 20.2% |
| 55Δ | 2.30 | 200.1% | 19.4% | 2.53 | 236.5% | 17.2% |
| 60Δ | 2.20 | 209.1% | 16.9% | 2.63 | 216.3% | 14.1% |
| 65Δ | 2.09 | 218.1% | 14.5% | 2.73 | 196.1% | 11.0% |
| 70Δ | 1.97 | 233.3% | 12.2% | 2.84 | 175.9% | 8.0% |
| 75Δ | 1.74 | 295.7% | 11.2% | 2.94 | 155.6% | 4.9% |
| 80Δ | 1.50 | 358.2% | 10.1% | 3.15 | 147.7% | 2.8% |
20Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
25Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
30Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 2.01
- IV
- 337.6%
- B/E move
- 32.5%
35Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 2.11
- IV
- 317.3%
- B/E move
- 29.4%
40Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 2.22
- IV
- 297.1%
- B/E move
- 26.4%
45Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 2.32
- IV
- 276.9%
- B/E move
- 23.3%
50Δ
- Pseudo strike
- 2.41
- IV
- 191.1%
- B/E move
- 21.8%
- Pseudo strike
- 2.42
- IV
- 256.7%
- B/E move
- 20.2%
55Δ
- Pseudo strike
- 2.30
- IV
- 200.1%
- B/E move
- 19.4%
- Pseudo strike
- 2.53
- IV
- 236.5%
- B/E move
- 17.2%
60Δ
- Pseudo strike
- 2.20
- IV
- 209.1%
- B/E move
- 16.9%
- Pseudo strike
- 2.63
- IV
- 216.3%
- B/E move
- 14.1%
65Δ
- Pseudo strike
- 2.09
- IV
- 218.1%
- B/E move
- 14.5%
- Pseudo strike
- 2.73
- IV
- 196.1%
- B/E move
- 11.0%
70Δ
- Pseudo strike
- 1.97
- IV
- 233.3%
- B/E move
- 12.2%
- Pseudo strike
- 2.84
- IV
- 175.9%
- B/E move
- 8.0%
75Δ
- Pseudo strike
- 1.74
- IV
- 295.7%
- B/E move
- 11.2%
- Pseudo strike
- 2.94
- IV
- 155.6%
- B/E move
- 4.9%
80Δ
- Pseudo strike
- 1.50
- IV
- 358.2%
- B/E move
- 10.1%
- Pseudo strike
- 3.15
- IV
- 147.7%
- B/E move
- 2.8%
Options history
Table
| Date | IV (%) |
|---|---|
| 139.39% | |
| 155.22% | |
| 140.36% | |
| 131.71% | |
| 151.30% | |
| 168.47% | |
| 184.38% |
Biotechnology
AUPH
Aurinia Pharmaceuticals Inc., a biopharmaceutical company, develops and markets therapies to treat various diseases with unmet medical needs in Japan and China. The company is…
More →AURA
Aura Biosciences Inc is a pioneering clinical-stage biotechnology company focused on transforming cancer treatment through its unique virus-like particle (VLP) technology. The…
More →AUTL
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T-cell therapies for the treatment of cancer. The company is headquartered in London, the United…
More →AVBP
ArriVent BioPharma, Inc. (AVBP) is a dynamic biopharmaceutical company dedicated to developing pioneering therapies that address critical unmet needs in oncology and autoimmune…
More →AVIR
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing antiviral therapies for patients suffering from viral…
More →AVLN
Avalyn Pharma Inc. is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for severe respiratory diseases, with its lead candidate, AV-101,…
More →